Business Context and Reporting Period
This Form 6-K filing by GlaxoSmithKline plc (GSK) covers the month of October 2021, specifically reporting a transaction notification dated October 13, 2021. The filing details a transaction involving a Person Discharging Managerial Responsibilities (PDMR) within the company.
Key Financial Metrics
This filing is a transaction notification and does not contain consolidated financial statements, revenue, profit, cash flow, margins, debt, or liquidity metrics for the company.
| Metric | Value |
|---|---|
| Transaction Type | Acquisition of Ordinary Shares |
| Instrument | Ordinary Shares of 25 pence each (ISIN: GB0009252882) |
| Transaction Price | £14.0080 |
| Transaction Volume | 8,752.509 shares |
| Transaction Date | October 11, 2021 |
| Exchange | London Stock Exchange (XLON) |
Material Changes
The filing reports a single transaction where Ms. E Walmsley, Chief Executive Officer, acquired Ordinary Shares. This acquisition resulted from the re-investment of dividends paid to shareholders on October 7, 2021, under the Company's Performance Share Plan. These shares are subject to a 2-year holding period. No material changes to the company's financial position or operations are reported in this document.
Guidance, Outlook, and Risks
The filing text does not provide guidance, outlook, management commentary on future performance, risks, contingencies, or unusual items. The document is strictly a regulatory disclosure of a specific insider transaction.
Investor Verification Checklist
- Verify the identity of the PDMR: Ms. E Walmsley (Chief Executive Officer).
- Confirm the transaction was an acquisition via dividend re-investment, not an open market purchase.
- Note the 2-year holding period restriction on the acquired shares.
- Check the transaction date (October 11, 2021) against the dividend payment date (October 7, 2021).
- Confirm the transaction occurred on the London Stock Exchange at a price of £14.0080 per share.